Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized NK Cell Therapy in CBT
NCT02727803Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- May 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NK-92 in leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started May 2016; status: recruiting.
02
Drugs
NK-92
03
Conditions
leukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02727803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727803.